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Abstract
Improved understanding of the immune events discriminating between seropositive arthralgia and clinical synovitis is
of key importance in rheumatology research. Ample evidence suggests a role for Th17 cells in rheumatoid arthritis.
We hypothesized that CD4+CD161+ cells representing Th17 lineage cells may be modulated prior to or after
development of clinical synovitis. Therefore, in a cross-sectional study, we investigated the occurrence of
CD4+CD161+ T-cells in seropositive arthralgia patients who are at risk for developing rheumatoid arthritis and in
newly diagnosed rheumatoid arthritis patients. In a prospective study, we evaluated the effect of methotrexate
treatment on circulating CD4+CD161+ T-cells. Next, we assessed if these cells can be detected at the level of the RA
joints. Precursor Th17 lineage cells bearing CD161 were found to be increased in seropositive arthralgia patients. In
contrast, circulating CD4+CD161+T-cells were decreased in newly diagnosed rheumatoid arthritis patients. The
decrease in CD4+CD161+ T-cells correlated inversely with C-reactive protein and with the 66 swollen joint count.
Methotrexate treatment led to normalization of CD4+CD161+ T-cells and reduced disease activity. CD4+CD161+ T
cells were readily detected in synovial tissues from both early and late-stage rheumatoid arthritis. In addition, synovial
fluid from late-stage disease was found to be enriched for CD4+CD161+ T-cells. Notably, synovial fluid accumulated
CD4+CD161+T-cells showed skewing towards the Th1 phenotype as evidenced by increased interferon-γ
expression. The changes in peripheral numbers of CD4+CD161+ T-cells in seropositive arthralgia and early
rheumatoid arthritis and the enrichment of these cells at the level of the joint predict a role for CD4+CD161+ T-cells in
the early immune events leading to clinical synovitis. Our findings may add to the development of RA prediction
models and provide opportunities for early intervention.
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Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune disease
characterized by joint inflammation of synovial tissue eventually
leading to cartilage and bone destruction. Early and
combination treatment strategies were shown to be effective in
controlling joint inflammation and prevention of bone erosions
[1]. Thus, early recognition of RA and identification of
individuals at risk for arthritis development would open
opportunities for early clinical intervention.
Autoantibodies such as rheumatoid factor (RF) and anti-
cyclic citrullinated peptide antibodies (ACPA or anti-CCP) can
be found in individuals already years before clinical synovitis
becomes manifest. In a prospective study design, arthritis
development in arthralgia patients was found to be associated
with anti-CCP status [2,3]. Of this seropositive arthralgia patient
(SAP) group, 35% developed arthritis after a median follow-up
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period of 12 months [3]. The majority of these patients (92%)
fulfilled the 2010 American College of Rheumatology (ACR)
criteria for classification of RA.
Understanding the immune events involved in the transition
to clinical synovitis, and translation of these insights into the
development of biomarkers is key [4]. Ample evidence
suggests a role for Th17 cells in the development of RA [5]. In
recent years, evidence was provided for the involvement of
Th17 cells in the initiation phase of RA. First, the development
of a cytokine environment favoring Th17 generation is an early
event in RA pathogenesis [6]. Second, in line with this, pre RA
patients were found to show increased serum levels of IL-17
prior to the manifestation of clinical synovitis but these levels
dropped significantly following the transition to RA [7]. Although
Th17 cells were detected in rheumatoid synovial tissue, Th17
cells appear to be outnumbered by interferon (IFN)-γ-producing
Th1 cells at the level of the inflamed joint [8,9]. The latter may
be explained by reprogramming of Th17 cells to Th1 cells by
synovial fluid derived IL-12, as shown in juvenile idiopathic
arthritis [10,11].
Human CD161 is the homologue of mouse NK cell receptor-
P1A and constitutes a type II transmembrane glycoprotein with
characteristics of the C-type lectin superfamily [12]. CD161 is
now considered a marker of Th17 lineage cells [13-15]. All
human IL-17 producing cells are thought to originate from
CD161+ precursors in umbilical cord blood and newborn
thymus [13]. CD161 expression is induced by RAR-related
orphan receptor C (RORC), the Th17 lineage transcription
factor [16]. It seems that CD161 expression is maintained
throughout the life cycle of the cell since it is detectable on
memory circulating and tissue infiltrating Th17, Th17/Th1 and
Th1 lymphocytes. CD161 expression thus presents a means to
determine Th17 ancestry in peripheral and tissue infiltrating
CD4+ T-cells [17,18].
We hypothesized that CD4+CD161+ T-cells representing
Th17 lineage cells are involved in the initiation phases of RA
and that peripheral numbers of these cells may be modulated
prior to or after the development of clinical synovitis. Therefore,
in a cross-sectional study, we investigated the occurrence of
CD4+ CD161+ T-cells in SAP, newly diagnosed, treatment-
naïve RA patients at baseline and at 3 and 6 months after start
of methotrexate (MTX) treatment. Next, we assessed if
CD4+CD161+ T-cells can be detected in early and late-stage
RA synovial tissue. In late-stage RA, paired samples of
peripheral blood and synovial fluid were studied. Our study
revealed altered numbers of peripheral CD4+CD161+ T-cells in
SAP versus early RA patients and a relative enrichment of
these cells in RA joints. The data suggest a role for




Rheumatoid arthritis (RA) and seropositive arthralgia patients
(SAP) gave their written informed consent. Twentyfour healthy
control (HC) volunteers were recruited in 2010 and 2011 for
establishing reference values on leukocyte subsets and T cell
cytokine production. Documented oral (n = 20) or written
informed consent (n = 4) was obtained. Documented oral
consent and anonymisation of HC blood samples by a
registered medical immunologist was approved by the
Institutional Review Board. At time of blood sampling, healthy
volunteer donors were requested to fill out a health
questionnaire. All procedures were in accordance with
institutional guidelines and approved by the local medical
ethics committee (UMCG Groningen, the Netherlands). METC
numbers: 2007.148, 2009.118, 2011.306 and 2012.375.
Study Populations
Starting February 2012, twenty-six patients with a positive
anti-CCP and/or IgM-rheumatoid factor (RF) status and (a
history of) arthralgia, but not arthritis, defined as SAP, were
recruited at the rheumatology outpatient clinic at the UMCG.
Absence of arthritis was confirmed by physical examination of
44 joints by a trained medical doctor and a senior
rheumatologist.
Thirty-five newly diagnosed, treatment-naive RA patients
were recruited starting in 2010. All patients fulfilled the ACR
1987 or 2010 criteria [19,20] with a mean duration of preceding
symptoms of 10,2 ± 16,5 months. Twenty-six and 12 RA
patients were followed prospectively for a period of 3 (14 ± 3
weeks) and 6 months (29 ±7 weeks) respectively after start of
MTX treatment.
Paired samples of peripheral blood (PB) and synovial fluid
(SF) were obtained from 11 RA patients with late-stage RA. All
of these patients fulfilled the ACR 1987 criteria and were
treated with different disease modifying anti-rheumatic drugs
(DMARDs, e.g. MTX, Etanercept, Adalimumab and
Prednisolone).
Twenty-four healthy subjects, matched for age, sex and
ethnicity, were included as a control group. Exclusion criteria
were inflammation, malignancy (past or present), or use of
immune suppressive drugs.
Demographic and clinical characteristics of patients and
controls are summarized in Table 1. In addition, synovial
tissues (ST) were obtained from 15 early, treatment naïve RA
patients undergoing knee or ankle arthroscopy. Four out of 15
biopsy tissues contained clear cellular infiltrates and were
processed for immunohistochemistry (IHC, n = 4. Three out of
4 were female, median age of 60.5 (range 53,2 - 67,8), 3 out of
4 were anti-CCP positive and all 4 were RF positive). In
addition, we obtained ST biopsies from 4 RA patients with late-
stage, active RA (All 4 patients were female with a mean age of
54,0± 4,4; C-reactive protein (CRP) median value (range) of
24,0 mg/L (7,0-63,0); erythrocyte sedimentation rate (ESR)
median value (range) of 48,5 mm/h (19,0-51,0); 1 out of 4 was
anti-CCP-positive; 3 out of 4 were RF-positive).
Anti-CCP and RF Determination
Anti-CCP serum levels were determined by anti-IgG CCP
fluorescent enzyme immuno assay on Phadia 250 (Thermo
Fisher Scientific, Uppsala, Sweden). RF total Ig serum levels
were determined by turbidimetry using modular analyzer
(Roche, Mannheim, Germany). Seropositive status was defined
Th17 Lineage Cells in RA Development
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as anti-CCP serum levels of ≥ 10 IU/mL and/or RF serum
levels of ≥ 15 IU/mL.
Flowcytometric Analysis of T-cell-surface Markers and
Cytokine Expression
The absolute numbers and the phenotype of lymphocytes in
PB and SF were determined using multicolor flowcytometry.
Briefly, 100 µl of EDTA anti-coagulated PB or SF was collected
and stained, according to the manufacturer’s instructions, with
combinations of the following antibodies: anti-CD4 PerCP, anti-
CD8 PerCP, anti-CD45RO FITC, anti-CCR7 PE, anti-CD161
Table 1. Demographic and clinical characteristics of
subjects included in the study.
   Longitudinal study  
 HC SAP Early RA Early RA Early RA Late-
   Baseline 3 months 6 months Stage RA
    MTX MTX  
N 24 26 35 26 12 11
Age [yrs] 58.8±10.4
55.2
±10.5 59.9 ±10.9 59.7 ±11.5 56.9 ±9.7 62.1 ±12.5
mean ± SD       
Gender (%
female) 79.2 65.4 80.0 77.0 42.0 63.6
SE (%




na na na na na 5.8
median
(range)      (2.4-43.9)
Erosive (%)
X ray na na 20.0 nd 33.3 63.6
CRP [mg/L] na 5.0 14.0 5.0 5.0 21.5
median
(range)  (5-29) (5-118) * (5-45) † (5-16) † (5-49) * #
ESR [mm/h] na 14.0 26.0 18.0 12.0 23.5
median
(range)  (2-69) (2-96) * (5-76) (4-55) (3-80)
RF (%
positive) na 73.1 74.3 76.9 83.3 63.6
Anti-CCP (%
positive) na 96.0 68.6 73.1 75.0 90.9
DAS28
(mean ± SD) na na 5.1 ±1.3 3.7 ±1.3 † 2.8 ±1.0 † 2.4 ±1.0 †
SE = shared epitope (SE-containing alleles are HLA-DRB1*0401, * 0404, * 0405, *
0408, * 0101, * 0102 and * 1001); CRP= C-reactive protein; ESR= erythrocyte
sedimentation rate; RF= rheumatoid factor (positive score defined as ≥ 15 IU/mL);
Anti-CCP= anti- cyclic citrullinated peptides antibodies (positive score defined as >
10 IU/mL); DAS28= disease activity score 28; nd = not determined; na = not
applicable. * p < 0.05 compared to seropositive arthralgia patients; † p < 0.05
compared to RA patients at baseline; # p < 0.05 compared to RA patients after 3
mo MTX treatment. Seropositive arthralgia patients (SAP) inclusion criteria were
anti-CCP and /or RF seropositivity and arthralgia affecting at least one joint.
doi: 10.1371/journal.pone.0079370.t001
APC (BD Biosciences, San Jose, CA, USA) or anti-CD3 eFluor
605NC, anti-CD4 eFluor450 (eBioscience, San Diego, CA,
USA), CD8 PerCP, anti-CD45RO FITC, anti-CCR7 PE-Cy7
(BD Biosciences), anti-CD161 PE ((Miltenyi Biotec, Leiden,
The Netherlands).
Absolute numbers of leucocytes, CD3 and CD4 T-cells were
determined using the BD MultiTest TruCount method with six-
color MultiTest reagents detecting CD45, CD3, CD4, CD8,
CD19, CD16+CD56 (BD) using a lyse-no-wash preparation
method as described by the manufacturer. Flowcytometry was
performed on FACSCanto II (BD) and analysis was performed
using FACSCanto Clinical Software (BD). CD4+ T-cells were
further characterized by analyzing expression of CCR7 and
CD45RO [21]. Percentages of T lymphocytes with a naïve
(TNaive), central memory (TCM), effector memory (TEM) and
terminally differentiated (TEMRA) phenotype within the total CD4
counts were used to calculate the absolute numbers of these
subsets.
To assess the potential of CD4+ CD161+ T-cells to produce
cytokines, 100 µl of heparinized PB or 100 µl of SF was
stimulated with phorbol myristate acetate (PMA) (50 ng/mL)
and ionomycin (1,6 µg/mL) in the presence of brefeldin A (BFA)
(10 µg/mL) (Sigma Aldrich, Zwijndrecht, The Netherlands) for 4
h at 37°C. After stimulation, erythrocytes were lysed with ice-
cold ammonium chloride buffer (pH 7,4 for 10 min on ice). Cells
were fixed and permeabilized using Fix & Perm Cell
Permeabilization Reagents (Life Technologies, Bleiswijk, The
Netherlands) and stained with anti- IFNγ PerCP-Cy5.5, anti-
tumor necrosis factor (TNF)-α PerCP-Cy5.5 (BioLegend, San
Diego, CA, USA), anti-CD3 eFluor605NC, anti-CD4 eFluor450,
anti-IL-17 FITC, Perforin FITC (eBioscience), anti-CD8 APC-H7
(BD) and anti-CD161 APC (Miltenyi Biotec). Mouse isotype
controls were used in parallel at the same concentrations. Cells
were analyzed using FACS Calibur and LSR II flowcytometers
(BD Biosciences), and data analysis was performed with
FlowJo™ software (Tree Star, Ashland, OR, USA).
Synovial Tissue and IHC
ST biopsies, obtained from 15 newly diagnosed, treatment-
naïve RA patients undergoing knee or ankle arthroscopy were
snap frozen and stored at -80 °C. Biopsy sections were first
analysed for the presence of cellular infiltrates. Clear infiltrates
were detected in 4 out of 15 patient biopsies. Positive biopsies
were examined for the presence of CD161-expressing T cells.
Cryostat sections (5 µm) were cut and stored at -20 °C. Air-
dried sections (30 min) were fixed with 3% paraformaldehyde
and 0.3% glutaraldehyde for 10 min. Sections were incubated
with 0.1% hydrogen peroxide (Merck, Amsterdam, The
Netherlands) for 10 min or Avidin/Biotin Blocking kit (Vector,
Burlingame, CA, USA) according to the manufacturer’s
instructions. Following washing, sections were incubated with
the primary antibodies: anti-CD161 (polyclonal rabbit anti-
human CD161 from Sigma-Aldrich) diluted 1:20, anti-CD3
(monoclonal mouse anti-human CD3 from Dako, Glostrup,
Denmark,) diluted 1:50, anti-CD4 (monoclonal mouse anti-CD4
from Lifespan BioSciences, Seattle, WA, USA) diluted 1:10 in
PBS for 1 hr at RT. Following washing, secondary donkey anti-
rabbit-alkaline phosphatase (AP) antibody diluted 1:200, goat
Th17 Lineage Cells in RA Development
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anti-mouse IgG1-biotin antibody diluted 1:100 and goat anti-
mouse IgG2a-HRP antibody diluted 1:200 (SouthernBiotech,
Birmingham, AL, USA) were used respectively. After incubation
for 1 hr, CD3 stained tissue sections were incubated with
streptavidin-AP (SouthernBiotech) for 30 min at RT. AP
substrate (Sigma-Aldrich) or HRP (Dako) were used according
to the manufacturer’s instructions. Tissue sections were
counterstained with hematoxylin (Merck).
Synovial Tissue and Cell Isolation
ST biopsies, obtained from late-stage RA patients
undergoing hip or knee joint replacement surgery, were rinsed
with Dulbecco’s modified Eagles Medium (DMEM, Life
Technologies), supplemented with 60 μg/mL gentamycin (Life
Technologies) and cut into small fragments using a scalpel.
The minced tissue was then incubated with 80 units/mL of
hyaluronidase from bovine testes (Sigma-Aldrich) at 37°C.
After 15 min. collagenase type IV from Clostridium histolyticum
(Life Technologies) was added (final concentration of 1 mg/
mL). Tissue was further digested, while rotating (225 rpm) for 2
hr at 37°C. After filtration and washing cells were stained with
the following antibodies: anti-CD3 eFluor605NC, anti-CD4
eFluor450 (eBioscience), anti-CD19 PerCP, anti-CD161 PE
(BD).
Statistical Analysis
Power analysis for the sample size calculation was
performed based on the results obtained from a pilot
experiment involving 20 RA patients and 20 HC. A 2-sided
power analysis was done with a confidence interval and power
of 95% and 90%, respectively. Results are expressed as mean
± standard deviation (SD) or median (range) for normally
distributed and non-normally distributed data, respectively.
Normally distributed data was analyzed using ANOVA and
unpaired t test. Non-normally distributed data was analyzed
using Kruskal-Wallis test and Mann-Whitney 2-tailed test.
Correlations between cell numbers and clinical data were
evaluated by nonparametric Spearman's correlation analysis.
Paired samples analysis was performed with Wilcoxon signed
rank test. Generalized estimating equations (GEE) analysis
was used to analyze parameters over time within patients.
Simple contrasts were used to compare follow-up visits to
baseline. Statistical analysis was performed with GraphPad
Prism version 5.0 (GraphPad Software, San Diego, CA, USA)
and IBM SPSS Statistics 20 (SPSS, Chicago, IL, USA). P<0.05
was considered statistically significant.
Results
Circulating Effector Memory Cells are increased in
Seropositive Arthralgia Patients when compared to
Newly Diagnosed RA
To identify immune markers associated with arthralgia and/or
clinical synovitis, we first assessed if the peripheral leukocyte
pool was altered in SAP and in newly diagnosed, DMARD-free
RA patients (when compared to healthy controls). Absolute
numbers of leukocytes, total T-cells and CD4+ T-cells were
comparable between groups (Table 2). Next, CD4+ T-
lymphocytes with a naïve (TNaive), central memory (TCM), effector
memory (TEM) and terminally differentiated effector memory
(TEMRA) phenotype, defined by expression of CD45RO and
CCR7, were assessed. Absolute numbers of TNaive, TCM, TEM and
TEMRA in SAP were similar to healthy controls. No statistically
significant differences were noted. Interestingly, absolute
numbers of TEM and TEMRA were significantly elevated in SAP
when compared to RA. In addition, absolute CD4+ TNaive counts
tended to be increased in SAP and were significantly increased
in newly diagnosed RA patients when compared to HC. The
latter phenomenon is in line with previous reports on expansion
of naïve phenotype cells in RA [22].
Table 2. Absolute numbers of circulating leukocyte subsets
in HC, SAP and RA patients.
 HC SAP RA Baseline
N 20 26 30
CD45+    
cell absolute count x106/mL, 1.89 1.91 1.86
median (range) (1.25-2.63) (0.89-12.3) (1.31-3.01)
CD3+    
cell absolute count x106/mL, 1.34 1.42 1.41
median (range) (0.93-1.80) (0.51-3.63) (0.83-2.50)
CD3+CD4+    
cell absolute count x106/mL, 0.96 1.00 0.90
median (range) (0.49-1.29) (0.39-2.44) (0.50-1.68)
CD4+ Naïve (CD45RO-CCR7+)    
cell absolute count x106/mL, 0.25 0.36 0.40 *
median (range) (0.09-0.58) (0.07-1.45) (0.15-0.95)
CD4+ Central Memory (CD45RO
+CCR7+)    
cell absolute count x106/mL, 0.28 0.28 0.28
median (range) (0.03-0.39) (0.12-0.84) (0.08-0.72)
CD4+ Effector Memory (CD45RO
+CCR7-)    
cell absolute count x106/mL, 0.26 0.31 † 0.25
median (range) (0.13-0.58) (0.11-0.53) (0.11-0.49)
CD4+ Terminally Differentiated EM    
(CD45RO-CCR7-)    
cell absolute count x106/mL, 0.020 0.034 † 0.018
median (range) (0.004-0.56) (0.005-0.23) (0.004-0.14)
* p < 0.05 RA patients at baseline vs HC; † p < 0.05 Seropositive arthralgia
patients (SAP) vs RA patients at baseline (Mann-Whitney test). The absolute
numbers of CD45+, CD3+, CD3+CD4+ lymphocytes were determined using the
BD MultiTest TruCount method. Relative values (%) of T lymphocytes with a naïve
(TNaive), central memory (TCM), effector memory (TEM) and terminally
differentiated effector memory (TEMRA) phenotype within the total CD4 counts
were used to calculate the absolute numbers of these subsets.
doi: 10.1371/journal.pone.0079370.t002
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Circulating CD4+CD161+ T lymphocytes are Increased
in Seropositive Arthralgia Patients but Decreased in
Patients with Newly Diagnosed RA
We next investigated circulating T-cells expressing the Th17
lineage marker CD161 in SAP and RA patients. Whereas
absolute numbers of CD4+CD161+ T-cells were found
increased in SAP, a significant decrease of these cells was
noted in newly diagnosed RA patients (Figure 1A, B). Similar
results were obtained when proportions of CD161+ T-cells
within the CD4 subset were calculated (Figure 1C). Next, we
assessed whether the decrease of the CD4+CD161+
population was associated with clinical measures of disease
activity. The absolute numbers of CD4+CD161+ T-cells as
seen in newly diagnosed RA correlated inversely with CRP (r =
-0,43 and P = 0.02, Figure 1D). Moreover, CD4+CD161+ T-
cells tended also to correlate inversely with the disease activity
score 28 (DAS28, r = -0,35 and P = 0.058, Figure 1E).
Absolute numbers of CD4+CD161+ cells did not correlate with
the 28 swollen joint count (SJC) (r = -0,26 and P = 0.18, Figure
1F) in which ankles and feet are not included. Interestingly,
absolute numbers of CD4+CD161+ cells were found to
correlate inversely with the total 66 SJC (r = -0,41 and P =
0.03, Figure 1G).
Previously, CD4+CD161+ T-cells were found to contain Th17
(defined by expression of IL-17 but not IFN-γ) and two progeny
subsets: Th17/Th1 (defined by expression of both IL-17 and
IFN-γ) and Th1 (the so-called non classical Th1 defined by
expression of IFN-γ but not IL-17) [17,18]. We assessed the
relative frequencies of these cells by analyzing the
CD4+CD161+ T-cell cytokine producing potential in the
different groups (Figure 1H-J). Frequencies of circulating Th17
cells tended to be increased in newly diagnosed RA when
compared to HC (Figure 1H). Th17/Th1 double positive cells
were found increased in SAP (Figure 1I). Non classical Th1
were found to be decreased in newly diagnosed RA when
compared to the SAP group (Figure 1J).
Circulating CD4+CD161+ T-cells normalize following
Treatment
Newly diagnosed RA patients were assessed at baseline
(before start of MTX treatment) and at 3 and 6 months after
start of treatment for absolute numbers of circulating
CD4+CD161+ T-cells and for clinical parameters of disease
activity. MTX treatment significantly reduced CRP and Disease
Activity Score (DAS)28, but not ESR, at 3 and 6 months when
compared to baseline (Table 1). Importantly, the reduction in
CRP and DAS28 was associated with an increase in the
absolute number of circulating CD4+CD161+ T-cells (Figure
2A, B). Notably, the numbers of PB CD4+CD161+ T-cells
increased to the level observed in healthy subjects at 3 and 6
months (Figure 2 C). The data merit further study into the utility
of circulating CD4+CD161+ T-cells as a potential biomarker of
synovitis in RA.
CD4+CD161+ T-cells are found at Inflamed Sites in RA
Joints
CD161 may function as an adhesion molecule and thereby
facilitate migration [14,23]. To assess if the observed decrease
of circulating CD4+CD161+ T-cells in newly diagnosed RA
patients may be explained by their homing to the site of
inflammation, we analyzed CD161 expression in ST samples
obtained via arthroscopy in this group. CD4+ CD161+ T-cells
were readily detected in ST sections using IHC. Representative
staining of consecutive synovial biopsy sections showed clear
staining for CD161 in the area’s infiltrated by CD3- and CD4-
expressing cells (Figure 3A-D).
Next, we investigated CD4+CD161+ T-cells in patients with
late-stage disease. To that end, relative frequencies of these
cells were assessed in paired samples of PB and SF. Also, we
assessed the presence of CD4+CD161+ T-cells in digested ST
biopsies by flowcytometry. The frequency of CD4+CD161+ T-
cells in the SF was significantly increased when compared to
PB (mean value 29,2% within the total CD4+ in SF vs. 18,7%
within total CD4+ in PB, Figure 3E). Similarly, flowcytometric
analysis of digested ST from late-stage RA showed an
increased frequency of CD4+CD161+ T-cells (median value
58,9% of total CD4+ in ST, Figure 3F). In contrast, we did not
observe an accumulation of CD8+CD161+ T-cells in SF or ST
(Figure 3G, H).
Synovial Fluid-derived CD4+CD161+ T-cells show
enhanced IFN-γ-producing Capacity
Since the CD4+CD161+ T-cells were detected at the level of
the joints, we further investigated the Th17, Th17/Th1 and Th1
phenotypes and analyzed their cytokine producing potential in
paired SF and PB samples from RA patients with late-stage
disease. Interestingly, the percentage of IL-17-producing cells
was significantly higher within the PB-derived CD4+CD161+
subset than the SF-derived subset (median value 5,1% vs.
1,6% within CD4+CD161+ in PB and SF, respectively, Figure
4A), while the capacity for production of both IFNγ and IL-17
was similar for PB- and SF- derived CD4+CD161+ T-cells
(Figure 4B). Of note, a significant increase in the frequency of
single IFNγ+ cells (non classical Th1) was seen in SF when
compared to PB (median value 39,0% vs. 18,8%; Figure 4C).
Expression of TNF-α was variable between CD4+CD161+ T-
cells from PB and SF (Figure 4D). Thus, CD4+CD161+ T-cells
in the joints of late-stage RA display a skewing towards a pro-
inflammatory IFNγ signature.
Discussion
A better understanding of the immune events in the switch to
clinical synovitis would open opportunities for prevention of RA
development [4]. Thus, the definition of biomarkers
discriminating between seropositive arthralgia and clinical
synovitis is eagerly awaited. We report on profound changes in
circulating precursor Th17 cells in SAP who are at risk of
developing RA and in newly diagnosed patients with RA
(before start of DMARD treatment). Whereas absolute numbers
of CD4+CD161+ T-cells were found increased in the
seropositive arthralgia group, a profound decrease of these
cells was found to mark the early RA state. The decrease in the
absolute number of CD4+CD161+ T-cells in early RA
correlated inversely with CRP and with the SJC66. MTX
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Figure 1.  Altered dynamics of circulating CD4+CD161+ T-cells in seropositive arthralgia patients and in newly diagnosed
RA patients.  (A) Representative dot plots showing proportions of CD4+CD161+ T-cells in the study groups. The absolute number
(B) and the frequency (C) of CD161+ cells within CD4+ T-cells from healthy donors (n=20), SAP (n=26) and early RA patients
(n=35; Mann-Whitney test). Horizontal line in the box represents the median value. Boxes represent interquartile range and
whiskers represent the actual range. Symbols outwith the boxes represent outliers. The correlation between the absolute number of
CD161+ cells within CD4+ T-cells and (D) CRP (mg/l), (E) DAS28, (F) SJC28 and (G) SJC66 in RA patients (n=30; Spearman
coefficient analysis). Frequency of CD4+CD161+ -cells expressing (H) IL-17, (I) IL-17 and IFN-γ or (J) IFN-γ alone within total CD4+
from HC (n=6), SAP (n=6) and early RA patients (n=6; Mann-Whitney test). Statistical significance is indicated as * p ≤ 0.05, ** p ≤
0.001, CRP= C-reactive protein, DAS= disease activity score, SJC= swollen joint count.
doi: 10.1371/journal.pone.0079370.g001
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Figure 2.  Circulating CD4+CD161+ T-cells normalize
following MTX treatment.  (A) DAS28 and (B) the absolute
number of CD4+CD161+ T-cells from RA patients at baseline
(newly diagnosed; n=30), after 3 months (n=22) and 6 months
(n=7) of MTX treatment (GEE analysis); (C) Comparison of the
absolute number of CD4+CD161+ T-cells between HC (n=20)
and RA patients at baseline (n=30; Mann- Whitney test) or RA
patients at baseline (n=30) and RA patients after 3 months
(n=26) or 6 months (n=12) of MTX treatment (Wilcoxon
matched pairs test). Horizontal line in the box represents the
median value. Boxes represent interquartile ranges and
whiskers represent the actual range. Statistical significance is
indicated as * p ≤ 0.05, ** p ≤ 0.001.
doi: 10.1371/journal.pone.0079370.g002
treatment led to normalization of CD4+CD161+ T-cells and
reduced disease activity.
Our findings add to earlier reports implicating Th17 cells in
the initiation phase of RA. Indeed, a cytokine environment
favoring Th17 generation is an early event in RA pathogenesis
[6]. Importantly, pre RA patients were found to show increased
serum levels of IL-17 prior to the manifestation of clinical
synovitis but these levels dropped significantly following the
transition to RA [7]. The reported drop in systemic IL-17 levels
is mirrored by our observation on the dynamics of Th17
precursor cells expressing CD161 in SAP (increase) and in
clinical synovitis (decrease). Moreover, the inverse correlation
with the SJC66 would suggest their homing to the joint. Indeed,
CD4+CD161+ T cells were readily detected in ST from both
newly diagnosed and late-stage RA patients. In addition,
synovial fluid from late-stage RA was found to be enriched for
CD4+CD161+ T-cells which is in line with the effector memory
phenotype of these cells ( [21] and own observations).
Migration of CD4+CD161+ T-cells to the joints is
mechanistically explained by CCL20 induced migration. CCL20
expression in SF and ST has been reported previously to
attract CCR6+ cells [24-26]. Notably, CCR6 expression is a
feature of CD4+CD161+ T-cells. Both CD161 and CCR6
expression were found to be Th17 lineage transcription factor
(RORC) dependent [16]. Transendothelial migration may be
facilitated by CD161 mediated adhesion [23].
Interestingly, we found that the decrease in Th17 precursor
cells was correlated with the SJC66 but not with the SJC28.
The SJC66 includes ankles and feet, and thus provides a more
comprehensive appreciation of joint involvement. This would be
in line with earlier reports suggesting that the joints of the feet
are important in very early RA [27].
In a prospective, longitudinal study, we demonstrated that
peripheral CD4+CD161+ T-cell numbers normalize following
regular MTX treatment. This may be explained by inhibition of
migration due to MTX-mediated reduction of pro-inflammatory
cytokines, chemokines and adhesion molecule expression in
the joints [28,29]. It is currently not know if MTX affects CCL20
production, the primary chemokine for Th17 lineage cells. Our
data thus reveal profound effects of MTX treatment on
peripheral numbers of CD4+CD161+ cells and call for caution
when interpreting data on cellular immune markers in patients
receiving immune suppressive treatment.
In this study, we examined the dynamics of Th17 precursor
T-cells in 3 unique cohorts of patients: in SAP who are at risk of
developing RA, in newly diagnosed RA patients before and
after start of MTX treatment and in late-stage RA. Previously,
Miao et al reported on increased relative frequencies of IL-17
producing CD4+CD161+ T-cells that correlate with disease
activity in RA [30]. This patient cohort had a mean disease
duration of 3-4 years and most of these patients were treated
with DMARDs. Thus, this study cohort can best be compared
to our late-stage RA group on treatment. Although these
authors did not report on absolute numbers of CD4+CD161+
cells, the reported percentages of IL-17 producing CD4+
CD161+ T-cells compare well with our data in late-stage RA
(mean of 5% with ranges between 2-10%).
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Figure 3.  CD4+CD161+ T-cells are readily detected at the level of the joint in newly diagnosed and in late-stage
RA.  Detection of T cells expressing CD161 in ST obtained from a newly diagnosed RA patient using IHC on consecutive cryostat
sections (Krenn score = 4 [37]). A representative example is shown (magnification 40x). Blanc (A), CD3 (B), CD4 (C), CD161 (D).
Analysis of the number of CD4+CD161+ T-cells from paired PB and SF and non-paired PB and ST from late-stage RA. Frequency
of CD161+ cells within (E, F) CD4+ and (G, H) CD8+ T-cells were compared between paired samples of PB and SF (n=6; Wilcoxon
matched pairs test) or PB and enzyme-digested ST (n=4; Mann-Whitney test).
doi: 10.1371/journal.pone.0079370.g003
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In late-stage RA, synovial fluid CD4+ CD161+T-cells showed
skewing towards the Th1 phenotype when compared to
peripheral blood CD4+CD161+ T-cells. This is in line with
previous data reporting on Th17 plasticity towards Th17/Th1
and Th1 cells [10,11]. The instability of the Th17 phenotype at
the level of the joint may be explained by synovial fluid derived
factors including IL-12 [11]. Alternatively, the plasticity of Th17
lineage cells at the level of the joint is explained by other
mechanisms involving ligation of CD161 with naturally
occurring ligands. The only confirmed endogenous ligand for
CD161 is lectin-like transcript 1 (LLT1) [31-33]. LLT1 is
expressed by activated antigen presenting cells and
lymphocytes [34]. Interestingly, CD161 cross linking in vitro
was shown to facilitate IFNγ production by T-cells [31,34].
Others reported on increased T-cell IL-17 production [35].
There is currently no data available on expression of LLT1 in
RA. More studies are needed to assess if CD161-LLT1 ligation
relays co-stimulatory signals and if this contributes to Th17
function and or Th1 skewing at the level of the joint in RA.
The search for biomarkers characterizing the transition to
clinical synovitis is eagerly awaited and would present
opportunities for prevention of RA. Also, candidate biomarkers
would add to prediction models that are currently being
developed [3,36]. Circulating Th17 lineage cells were increased
in patients at risk for developing RA but decreased in newly
diagnosed RA. MTX treatment led to normalization of
circulating CD4+CD161+ T-cells. The decrease of
CD4+CD161+ T-cells in early RA was associated with the
SJC66. An improved mechanistic understanding of
CD4+CD161+ T-cells in the switch to RA synovitis may
ultimately provide novel treatment options.
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